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Background: Malnutrition is a common complication in patients at the palliative stage of cancer. During the
curative phase of cancer, optimal enteral or parenteral nutrition intake can reduce morbidity and mortality, and
improve quality of life. When the main goal of treatment becomes palliative, introduction of artificial nutrition is
controversial. Although scientific societies do not recommend the introduction of artificial nutrition in all cases of
malnutrition, especially in hypophagic patients if their life expectancy is shorter than 2 months, considerable
differences in the use of parenteral nutrition in nonsurgical oncology practice are noted around the world. One
explanation is a paucity of well-conducted randomized controlled trials in these situations, and consequently, the
risk/benefit ratio of parenteral nutrition and its impact on quality of life in palliative care remains uncertain.
Methods/design: The ALIM-K study is a French national multicenter randomized controlled trial designed to
evaluate the effectiveness of parenteral nutrition, versus an exclusive oral-feeding supply, on the quality of life of
malnourished patients who have a functional digestive tube and who are at the palliative phase of advanced cancer
with a life expectancy of more than 2 months.
Discussion: This article presents the methodologic options chosen for our study, and in particular, the choice of
the Zelen method of randomization, the definition of the main end point (quality of life), the choice of comparator
(oral feeding), and the inclusion criteria (life expectancy of more than 2 months), which are all critical points in
building a randomized controlled trial in the setting of palliative care.
Trial registration: This study was registered with the clinical trials database ClinicalTrials.gov on May 27, 2014,
under the number NCT02151214.
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Malnutrition in cancer patients is well established as a
contributor to morbidity and mortality, and its preva-
lence remains high, despite considerable progression in
cancer therapy over the last 10–year period. According
to reports, malnutrition affects 20% to 50% of cancer
patients [1], and its consequences in terms of morbidity
and mortality are well described [2,3]. Anticancer* Correspondence: lionel.pazart@gmail.com
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unless otherwise stated.treatments compound this situation by the addition of fre-
quent digestive disorders (nausea, vomiting, abdominal
cramps, mucitis, paralytic ileus, malabsorption). The
sometimes severe vomiting despite adjunctive use of an-
tiemetics or optimization of chemotherapy regimens
can also be a possible cause of malnutrition.
In the last few years, malnutrition in cancer has gar-
nered increasing attention, and this is reflected by the
publication of specific guidelines and research reports,
whose number has increased by 84% in the last 5 years
(131 publications) as compared with the previous 5 years
(71 publications) (based on a Medline search for thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Trials OR meta-analysis OR guideline” as filters, as per-
formed on August 12, 2014).
Accordingly, the European Society for Parenteral and
Enteral Nutrition (ESPEN) has published specific guide-
lines for the use of artificial nutrition in cancer patients
in the nonsurgical context [4,5]. For patients undergoing
curative treatment, management of malnutrition is based
on enteral nutrition when the digestive tract is func-
tional, and parenteral nutrition is indicated for patients
whose digestive tract is not functional (for example, in
patients with peritoneal carcinosis with intestinal occlu-
sion in the context of gynecologic cancers). Parenteral
nutrition offers the possibility of increasing or ensuring
nutrient intake in patients in whom normal food intake
is insufficient and enteral nutrition is either not feasible,
contraindicated, or not accepted by the patient [5]. The
duration of this type of nutrition can be up to several
months. This type of artificial nutrition yields a signifi-
cant increase in survival, and also a significant gain in
terms of disease-related morbidity [4-6]. Serious compli-
cations can occur in the short, medium, or long term,
and mainly comprise catheter infections, septic compli-
cations, hyponatremia, hypokalemia, hypomagnesemia,
hypophosphatemia, or hyperglycemia, resulting in dehy-
dration with electrolyte disturbances. These in turn may
cause coma, hypertriglyceridemia, or hepatobiliary com-
plications in the longer term, with risk of progression to
active fibrosis and cirrhosis.
Considerable controversy remains as to whether artifi-
cial nutrition should be introduced at the palliative stage
of cancer. The European Society for Parenteral and En-
teral Nutrition (ESPEN) has published specific guidelines
for the use of artificial nutrition (enteral or parenteral)
in end-stage cancer [4,5]. Despite efforts by scientific so-
cieties to be restrictive with the indications for artificial
nutrition, wide variations in the use of parenteral nutri-
tion in nonsurgical oncology practice exist around the
world. Withdrawing or withholding artificial nutrition in
palliative care is often interpreted by the patient, their
family, and/or the caregivers as an abandonment that
can often lead to ethical dilemmas among health care
providers [7]. Health care providers seem to lack infor-
mation [7] and consensus regarding the introduction or
withdrawal of artificial nutrition at the end of life, and
most existing guidance stems from expert agreement,
with a low level of evidence [8].
In case of end-stage cancer, the results are even less
salient, and to date, few clinical studies have evaluated
the risk-benefit ratio of artificial nutrition in the context
of palliative care. Agreement exists among all healthcare
professionals that it is not advisable or desirable to intro-
duce artificial nutrition in an aphagic or hypophagic pa-
tient at the end stage of cancer, if their life expectancy isshorter than the expected duration that it would take to
die of starvation (that is, less than 2 months) [8,9]. Con-
versely, it is unclear what should be done for such pa-
tients with incurable cancer when life expectancy is
longer than 2 months.
A major source of controversy in daily practice arises
from the involvement of several different specialists, who
each focus on different outcomes. For example, the on-
cologist focuses on reducing tumor growth and improving
survival, whereas the nutritionist focuses on balancing
food intake and biologic parameters, whereas supportive
carers are primarily concerned with the well-being and
quality of life of the patient. Unfortunately, it is not un-
common for oncologists to persist with their treatment
objectives, even when some consider that artificial nutri-
tion could accelerate tumor growth. Nutritionists and die-
titians cite the benefits of a balanced diet in responding to
energy needs, thus helping the patient to feel better.
Last, palliative or supportive caregivers are reluctant to
administer parenteral feeding, for fear of a futile and risky
intervention, which could lead to serious complications
and loss of autonomy with unnecessary prolongation of
the patient’s suffering and end-of-life process, rather than
extending survival with an acceptable quality of life.
One of the main objectives of palliative care is the im-
provement of, or failing that, maximizing delay in the
deterioration of health-related quality of life. In this con-
text, the expected favorable effects are counterbalanced
by the constraints and complications related to artificial
nutrition, particularly when oral feeding is still possible.
Thus, artificial nutrition is not recommended in patients
if the nutritional status, and/or calorie intake, remain
satisfactory [8,9].
A recent nationwide cross-sectional study performed
by the research network in palliative care in Sweden
(PANIS) described off-label use. The authors studied
1,083 patients with malignant tumors at the palliative
stage, and noted that 13% were receiving artificial nutri-
tion [10]. The data showed that parenteral nutrition was
the most frequent type used (in two thirds of cases),
with wide regional variations. Other countries have re-
ported almost systematic use of artificial nutrition in this
context (80% of patients at admission to the Seoul main
hospital, and up to 83% at 2 days before death) [11].
Weight loss and loss of appetite were the main reasons
justifying initiation of artificial nutrition, despite the pos-
sibility of oral feeding. Initiating artificial nutrition at
this stage of disease seems to be less guided by scientific
evidence, and more by subjective motivations linked to
beliefs, cultural or religious traditions, the symbolism of
the function of eating, the deep-seated fear of dying of
hunger, and the vision of care.
Parenteral nutrition could contribute to maintaining or
improving autonomy, thanks to increased muscle mass,
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general well-being. Only one randomized controlled trial
to date has shown that parenteral nutrition prolongs over-
all survival of cachexic patients, as compared with oral
feeding alone, associated in both arms of the study with
cyclooxygenase, insulin, and erythropoietin treatment [12].
The risk-benefit ratio of parenteral nutrition, particularly
in terms of health-related quality of life, is thus poorly
documented among patients with malnutrition but with a
functional digestive tract during the end stages of cancer.
Therefore, we initiated a randomized, controlled trial
to evaluate the clinical benefit, as assessed by patients’
health-related quality of life, of supplemental parenteral
nutrition versus no parenteral nutrition, in the context
of palliative care at the end stage of cancer.
Hypotheses and objectives
In view of the uncertainty regarding the risk/benefit ra-
tio of supplemental parenteral nutrition, we aim to in-
vestigate which of two management options (initiation
of supplemental parenteral nutrition or no introduction
of parenteral nutrition) proves to be superior in terms of
health-related quality of life without a significant de-
crease in survival, in the palliative phase of cancer.
The primary objective of the ALIM-K study is to evalu-
ate the clinical benefit in terms of health-related quality of
life, as evaluated at 2 months (or at treatment discontinu-
ation for patients who discontinue treatment allocation
before 2 months), by using the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire Core 15 Palliative (QLQ-C15-PAL),
and in particular, the physical function, global health, and
fatigue subscales [13], of the initiation of supplemental
parenteral nutrition as compared with no parenteral nutri-
tion, in malnourished cancer patients at the palliative stage
who have a functional digestive tract, and in the absence
of any curative therapy.
Secondary objectives are to compare the effects of
both types of nutrition on overall survival and nutri-
tional parameters.
Trial design
We initiated a multicenter, prospective, 1:1 randomized,
controlled, parallel-group trial. The experimental arm
consists of initiation of supplemental parenteral nutrition.
The control arm consists of pursuing oral feeding alone.
To minimize the difficulty of obtaining informed consent
and to stimulate accrual, we used the Zelen single-consent
design [14] to randomize patients before informed consent
has been obtained. After randomization has been per-
formed, only patients allocated to the intervention group
are approached and asked to consent to the study inter-
vention (parenteral nutrition in this case). According to
Zelen, patients allocated to the control group and receivingthe standard of care (oral feeding in this case) do not
need to be informed because these patients are simply
going to receive the usual therapy, and therefore, do not
constitute a “study population”. Patients allocated to the
intervention group who refuse consent are reassigned
to the control group.Methods/design
Participants, interventions, and outcomes
Study setting
This study will be conducted nationwide in France in nine
comprehensive cancer centers selected for their expertise,
and qualified to treat patients with more-advanced cancers,
as well as in two university teaching hospitals (University
Hospital of Besançon and Henri Mondor Hospital, Creteil,
France).Inclusion and exclusion criteria (Table 1)
Inclusion criteria are as follows: adult patients (aged
>18 years) with cancer at the palliative stage (that is, pa-
tients in whom the main aim of treatment is to limit
pain and discomfort). In these patients, curative treat-
ment either has been discontinued, or may still be on-
going but with little expected benefit in terms of overall
survival. Life expectancy must be longer than 2 months.
To be eligible, patients must have a functional digestive
tract and present malnutrition [15-17], defined as a body
mass index (BMI) <18.5 kg/m2 in patients aged <70 years
or <21 kg/m2 in patients aged ≥70 years; or weight loss
of 2% in 1 week, 5% in 1 month, or 10% in 6 months. Pa-
tients with antalgic radiotherapy or scheduled to undergo
palliative surgery may be included. Patients must already
have a functional central venous catheter in place.
Exclusion criteria are as follows: nonfunctional digest-
ive tract (intestinal occlusion, tumor compression, sub-
occlusive peritoneal carcinosis); any disorder preventing
oral ingestion (cancer of the upper aerodigestive tract,
esophagus, or stomach); parenteral nutrition that is on-
going or dating from less than 1 month; intravenous
chemotherapy through a pump lasting >48 hours, as
this is incompatible with administration of parenteral
nutritional through the central venous line; presence of
gastrostomy or jejunostomy; or persisting sensation of
hunger in aphagic patients. We will also exclude patients
with hematologic cancers undergoing bone marrow trans-
plant, patients with acute renal failure (defined as creatin-
ine clearance <30 ml/min) or heart failure (defined as a
left ventricular ejection fraction <30%); adult patients
under legal guardianship or those unable to respond to
the quality-of-life questionnaire (due to psychiatric disor-
ders, attention disorders, or cognitive disorders). Patients
participating in another ongoing clinical trial will also be
excluded.
Table 1 Inclusion and exclusion criteria for participants
Inclusion criteria Exclusion criteria
Adult patients (aged >18 years) with cancer at the palliative stage Any disorder preventing oral ingestion (cancer of the upper
aerodigestive tract, esophagus, or stomach)
Specific curative treatment discontinued or still ongoing but with little
expected benefit in terms of overall survival
Nonfunctional digestive tract
Life expectancy greater than 2 months Symptomatic peritoneal carcinosis
Malnutrition defined as Body Mass Index <18.5 kg/m2 if age <70 years,
<21 kg/m2 if age ≥70 years; or weight loss of 2% in 1 week, or 5% in
1 month, or 10% in 6 months
Hematologic malignancies
Patient no longer experiences a sensation of hunger Myocardial infarction or stroke in the previous 6 months
Patient has lost appetite Acute renal insufficiency (creatinine clearance < 30 ml/min) or heart
failure (left ventricular ejection fraction <30%)
Patient has reduced food intake Parenteral nutrition ongoing or dating from <1 month
Functional central venous catheter in place Presence of gastrostomy or jejunostomy
Functional digestive tract Persisting sensation of hunger
Patient able to understand and speak French Inability to complete quality-of-life questionnaires (due to psychiatric
disorders, attention disorders, or cognitive disorders).
Patients participating in another ongoing trial
Adult patients under legal guardianship
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Two groups will be constituted by random allocation. In
the intervention group (“parenteral nutrition” group),
parenteral nutrition will be initiated, whereas in the con-
trol group (“oral feeding” group), nutrition will be exclu-
sively by the oral route, without parenteral nutrition.
At inclusion, patients in both groups will be evaluated
by a dietitian with the aim of allowing all patients, regard-
less of the treatment group to which they are allocated, to
pursue oral feeding where possible. Initial evaluation will
record the following data:
➢ Anthropometric data (weight, ideal weight, height, BMI)
➢ Dietetic advice given (previously or during
evaluation) regarding uncomfortable symptoms
➢ Estimation of theoretic energy requirements in kcal
[18] adjusted by a correction factor for the cancer
➢ Estimation of theoretic protein requirements (1.2 to
1.5 g of protein per kilogram (kg) per day) [19]
➢ Quantitative estimation of daily intake in terms of
calories and protein (over 24 hours, as reported by the
patient)
➢ Visual or verbal analog scale of calorie and protein
intake (measured on a scale from 0 to 10)
➢ Number of eating intakes per day
➢ Oral nutritive supplements: type, dose, and protein-
energy content.
The dietitian’s main tasks will be as follows:
➢ To provide appropriate dietetic advice aimed at
spacing out and enriching food intake➢ To provide specific advice on the management of
symptoms related to food intake, such as anorexia, dry
mouth, early satiety, dysgeusia, nausea, vomiting,
chewing/swallowing disorders, transit disorders
➢ To propose, where necessary, prescription of oral
nutritional supplements.
In the “oral feeding” group, patients will pursue exclu-
sive oral feeding as usual, tailored to the patient’s needs
by a dietitian or nutritionist, according to local practice
in each center.
In the “parenteral nutrition” group, parenteral nutri-
tion will be initiated in accordance with current national
standards [20], which recommend implementation of
parenteral nutrition through a central intravenous line
(because the expected duration of use is longer than
2 weeks), to limit the risk of chemically induced phlebitis
and to preserve peripheral venous capital. In the context
of cancer, the prior presence of an implantable chamber
for specific chemotherapy will facilitate administration
of parenteral nutrition. Parenteral nutrition through a
central line makes it possible to use hyperosmolar mix-
tures that, thanks to the high rate of flow of the vena
cava, do not present significant venous toxicity. The dis-
pensing conditions (continuous or cyclic) and recom-
mended products are detailed later.
Type of product Pharmaceutical ternary mixtures will be
used, especially those with electrolytes, to limit at-risk
handling. No specific brand or product is recommended
for the study; each participating center is free to adminis-
ter parenteral nutrition in accordance with their local
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into account in the analysis at the end of the study. Micro-
nutrients will be systematically added to the mixture daily
via a vial of multivitamins and oligoelements. The addition
of electrolytes (sodium, potassium) will be adapted to the
patient’s requirements, and added to the mixture if no as-
sociated infusion is present. Vitamin K supplementation
will also be adapted to the patient’s requirements (by
evaluation of vitamin K-dependent factors). Finally, mag-
nesium and phosphorus supplementation will be provided
as needed.
Energy intake The exact modalities of parenteral nutri-
tion will be left at the physician’s discretion, with the
possible help of a dietitian. The recommended dose for
an aphagic patient will be 25 to 35 Kcal/kg/day, with 1.2
to 1.5 g/kg/day proteins. Daily intake must not exceed
1.25 times the resting energy expenditure, as calculated
by using the Harris-Benedict equation. Energy intake
will be adapted according to residual oral food intake,
with at least 1,000 Kcal/day and 6 g of nitrogen, on
5 days of 7.
Administration and follow-up Parenteral nutrition will
be administered via a central venous line (venous catheter
or implanted port). The flow rate of the intravenous infu-
sion by the central line must be regular, controlled with a
pump (±5%). Flow rate for infusion of carbohydrates must
not exceed 4 mg/kg/min; the daily dose of lipids will be
<1 g/kg/day. Cyclic administration (over 12 hours at night)
is now considered standard practice because of the numer-
ous advantages of this technique, including greater auton-
omy for the patient, possibility to maintain physical activity,
preservation of the physiological alternation between fasting
and food intake, the frequent association with oral feeding,
and better hepatic tolerance. Patients may be managed in
the hospital or at home.
Explanation of the choice of comparators
In the context of palliative care for advanced cancer in
patients with a functional digestive tract, current na-
tional guidelines in France do not recommend artificial
nutrition [8,9]. Thus, the standard of care in this study
will be exclusive oral feeding. Enteral nutrition is gener-
ally to be avoided in this context, because of its invasive
nature and the low tolerance for a stoma catheter or
nasogastric feeding tube in conscious patients, and also
because it may appear to be a disproportionate measure
in this population with limited vital prognosis.
Criteria for discontinuing or modifying allocated
interventions
Parenteral nutrition may be discontinued at any time by
the investigator or by the patient. Discontinuation ismandatory in case of uncontrolled hydroelectrolyte im-
balance, insulin-dependent diabetes with persistent fast-
ing glycemia >2 g/L, triglycerides >3 mM, or intra- or
extraluminal infection.
If the treating physician of a patient allocated to the
“oral feeding” group decides, during follow-up, to initiate
enteral or parenteral nutrition (irrespective of the rea-
son, including at the request of the patients or their
close relatives), follow-up within the ALIM-K study will
continue according to the modalities stipulated for the
group to which the patient was initially randomized.
In case of serious adverse events or effects leading to
discontinuation of the type of feeding intended for the
group to which the patient was initially allocated, the pa-
tient will be followed up according to the modalities
stipulated for that group, because follow-up corresponds
to standard recommended practices.
The investigator may decide at any time to change the
patient’s management, whether for reasons related to
safety, behavior, or administrative requirements, or for
any other reason the investigator judges relevant.
Strategies to improve adherence to intervention protocols
In randomization with the Zelen design [14], patients
are allocated to the treatment group before being
approached for informed consent. Patients allocated to
the “oral feeding” group will thus be treated in accord-
ance with standard practices, and the Hawthorne effect
should be minimized because the Zelen design obviates
the need to inform the patient about the idea of partici-
pating in a randomized study. Thus, using the Zelen de-
sign reduces the difficulty of obtaining informed
consent, and increases the rate of participation in the
study, by removing the psychological barriers linked to
lack of understanding of the need for random allocation
in deciding which therapeutic approach to choose, par-
ticularly for a patient at the palliative phase of advanced
cancer.
Relevant concomitant care and interventions that are
permitted or prohibited during the trial
No medication is prohibited in the context of the study.
All medications usually prescribed for the management
of patients may be administered.
Outcomes
Primary outcome The primary end point is health-related
quality of life specific to the palliative phase of cancer, eval-
uated at 2 months (or at treatment discontinuation for
patients who discontinue treatment allocation before
2 months), by using the European Organisation for Re-
search and Treatment of Cancer (EORTC) Quality of
Life Questionnaire Core 15 Palliative (QLQ-C15-PAL),
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fatigue subscales [13].
The QLQ-C15-PAL will be proposed to the patient at
inclusion in the study, and at every follow-up visit until
death. If necessary, help is available for patients to
complete the questionnaire (reading out the questions,
explaining the different response options, taking any
notes). The QLQ-C15-PAL is the short version of the
QLQ-C30 adapted for patients in palliative care [13].
The 15 items are divided into two functional subscales
(physical function, three items; and emotional function,
two items); two symptom subscales (fatigue, two items;
and pain, two items); five single items (dyspnea, appetite
loss, sleeping disorders, constipation, and nausea/vomit-
ing), and one item evaluating global health status/quality
of life. Linear transformation of the item responses yields
a score for each subscale (or single items) ranging from
0 to 100. A higher score corresponds to a higher level of
global quality of life and functional aspects, and a
greater level of symptoms on the symptom scale. The
subscales physical function, global health status/quality
of life, and fatigue will be evaluated for the primary end
point. The minimum clinically significant difference is
fixed at 10 points [21].
Secondary outcomes Secondary end points are as follows:
➢ Overall survival, defined as the time from the date
of randomization until death of any cause. Patients
who are still alive at the end of the study will be
counted at the date of last follow-up.
➢ Other (non-primary-end point) domains of the
QLQ-C15-PAL questionnaire (pain, emotional
function, nausea/vomiting, appetite, dyspnea,
constipation, and sleep) at 2 months (or at treat-
ment discontinuation for patients who discontinue
allocated treatment before).
➢ Longitudinal analysis of all domains of the QLQ-
C15-PAL.
➢ Nutritional parameters: weight, C-reactive protein
(CRP), prealbumin, albuminemia.
➢ For patients at the end-of-life stage: the Quality of
Life at End of Life (QUAL-E) questionnaire will be
administered by a clinical research assistant and
completed based on the patient’s responses. This
questionnaire has been validated in the English-
language version [22], and a cross-cultural validation
into the French language has been completed [23].
The French-language version comprises 25 questions
(compared with 24 in the English version) plus one
global question, covering five domains:
 life completion
 relationships with the health care system
 preparation/anticipatory concerns symptom impact
 connectedness and affective social support
The five possible response modalities for each item are
coded from 1 to 5. The score for each domain is calculated
by summing the responses for each item. The global
QUAL-E score is the sum of all 26 items. Linear transform-
ation yields score values ranging from 0 (lowest quality of
life) to 100 (highest quality of life). The scores from the in-
dividual domains of the QUAL-E will also be analyzed.
In the “parenteral nutrition” group, the following in-
formation will be recorded:
➢ Quantity and duration of treatment actually
administered.
➢ Biologic results from blood samples taken more
than 4 hours after the end of infusion of the last bag
of mixture, including blood gases, evaluation of
phosphorus, magnesium and calcium levels, hepatic
enzymes and triglycerides, and evaluation of
glycosuria and ketonuria.
➢ Any and all adverse effects.Time schedule for participants (see Table 2)
Day −7 to day 0: Patients who meet the inclusion cri-
teria will be identified from medical files or from regular
staff meetings or multidisciplinary case reviews, by the
oncologist or the treating physician from palliative care.
Once identified, eligible patients will be randomized
through a dedicated website, and will be allocated to
either the “parenteral nutrition” or the “oral feeding”
group. After randomization, the patient will be given
the appropriate patient-information leaflet for the allo-
cated group, after oral information has been provided to
the patient.
Day 1: The informed consent form, duly signed by the
patient and the investigator, will be retrieved by a clin-
ical research assistant. A first consultation will take
place at this time to perform standard clinical evalu-
ation and, in particular, to identify and manage any fac-
tors that might potentially promote anorexia and
digestive disorders. Performance status will be evaluated
by using the Karnofsky score, demographic and socio-
economic data will be recorded, and a complete nutri-
tional evaluation, including CRP, albumin, and prealbumin
will be performed in all patients. Patients allocated to the
parenteral nutrition group will also undergo biological
tests before initiation of nutrition. A consultation with a
dietitian will be held for all patients. No systematic dietetic
follow-up is planned for the study; the cadence of the
follow-up consultations is left to the discretion of the rele-
vant healthcare professionals in accordance with their
standard practice.
Table 2 A schematic diagram of time schedule for enrolment, interventions, assessments, and visits for participants
Pre-randomization (day -7 to day 0): Check inclusion and exclusion
criteria
Zelen's randomization
Parenteral nutrition group Oral feeding group
Present "parenteral nutrition" info Present "oral feeding" info
Day 1 Days 2-60* Day 61-death** Day 1 Days 2-60* Day 61-death**
Obtain informed consent X X
Record demographic data X X
Take medical history X X
Treatment
Concomitant treatments X X X X
Specific treatment (prior or ongoing) X X X X
Patient status
WHO Status X X X X X X
Karnofsky index X X X X
Estimated life expectancy X X
Anthropometric data
Height X X
Weight X X X X X X
Biology
Lactic acid dehydrogenase X X
C-reactive protein, albumin, prealbumin X X X X
Blood count, electrolytes (including phosphorus, calcium, magnesium) X X
Hepatic enzymes (AST, ALT, PAL, Gamma GT, Bilirubin) X X
Triglycerides X X
Ketonuria, glycosuria X X
Quality of life questionnaires (QLQ-C15-PAL and QUAL-E***) X X X X X X
Socio-economic variables X X
Dietetics consultation X X
Ingesta questionnaire X X X X
Evaluation of metastatic disease X X
Intervention supportive care X X
*Follow-up consultation at least once per month **Evaluation once per month. ***Administer the QUAL-E if the patients consider themselves to be at the end of
life (definition at the discretion of the physician and patient).
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and patients who are aware of the palliative status of
their disease will also complete the QUAL-E.
From day 1 to day 60: Patients will have regular follow-
up consultations during the follow-up period; at least
once per month, based on the patient’s planned attend-
ance at the hospital (for oncology consultations or
scheduled admission). The Karnofsky index, quality-of-life
evaluation, and details of energy intake will be recorded at
each consultation. Nutritional parameters (weight, CRP,
prealbumin, albumin) will also be recorded for all pa-
tients. Adverse effects will be reported, and seriousadverse events will be declared to the relevant pharma-
covigilance authorities in the University Hospital of
Besancon, France. For patients in the parenteral nutri-
tion group, quantity and duration of nutrition actually
administered will be recorded, and complete biological
evaluation will be performed (including blood gases,
evaluation of phosphorus, magnesium and calcium levels,
hepatic enzymes and triglycerides, and evaluation of glyco-
suria and ketonuria).
Beyond 2 months of treatment, discontinuation or not
of parenteral nutrition will be left to the physician’s
discretion.
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weight, and performance status by using the Karnofsky
index will be recorded once per month. Any serious ad-
verse events will be declared to the relevant pharmaco-
vigilance authorities.
Assignment of interventions
The study will comprise two arms: one intervention group
(parenteral nutrition group) and one control group (oral
feeding group). The Zelen single-consent design requires
that consent be obtained only from the intervention group,
for their participation in a study involving initiation of
parenteral nutrition. The patient will be informed of the
study requirements (inclusion criteria, aims, composition,
expected effects and benefits, foreseeable risks, contraindi-
cations and so on) to allow them to decide whether to con-
sent to participate. The information delivered to the patient
will not mention randomization. Patients allocated to the
oral feeding group will be informed about their manage-
ment, and will consent only to completion of the quality-of-
life questionnaire. Patients randomized to the intervention
group may refuse to consent to the intervention, in which
case, they will be included in the control group.
The distribution of patients between the study arms will
be performed by the investigator during the first consult-
ation to verify eligibility criteria, by means of Internet ac-
cess to a 1-to-1 randomization list, balanced by center,
and generated automatically by using SAS software (ver-
sion 9.3; SAS Institute Inc., Cary, NC, USA) and adminis-
tered by the Clinical Investigation Centre of the University
Hospital of Besancon, France.
Sample size and recruitment
In a bilateral situation, a P value of <0.0166 will be consid-
ered clinically and statistically significant after Bonferroni
adjustment for multiple testing, to ensure an overall bilat-
eral alpha risk of 5%. To detect the minimal clinically sig-
nificant difference (at least 10 points, with a standard
deviation of 11 points), with a bilateral alpha risk of 0.0166
and a power of 80%, 54 patients per group are required.
Interim analysis to evaluate the primary hypothesis is
planned when half the patients have been included and
have at least 2 months of follow-up. This interim analysis
will be performed according to the rules established by
O’Brien and Fleming (Alpha Spending Function with
bounds calculated by O’Brien’s method) [24].
The calculation of the sample size takes into account
the specificity of the randomization by the Zelen design,
and the primary end point of quality of life measured
with a multidomain questionnaire:
– Two groups of equal size, constituted by random
assignment; one group will receive standard therapy,
and the other group will receive the experimentaltherapy, or standard therapy if the patients refuses
to consent to experimental therapy. The
heterogeneity of the intervention group will increase
the variance of the difference (Δz) between groups
for the primary end point, as compared with classic
randomization (Δc), albeit without introducing a
measurement bias. The increase in variance will
increase with the percentage (Φ) of subjects who
receive standard treatment in the intervention group,
with Variance Δzð Þ ¼ Variance Δcð Þ= 1−Φð Þ2 [25].
In these conditions, the number of subjects must be
multiplied by (1/(1 - Φ)2). For the ALIM-K study, we es-
timate that the percentage (Φ) of subjects who receive
standard treatment in the intervention group will be low
(estimated at around 10% by experts).
– Quality of life, as measured by the questionnaire, will
yield a score for each domain. To take into account
the multiplicity of comparisons, the Bonferroni
correction will be applied to the alpha risk.
– A variation in quality-of-life score of at least 10
points (on a scale of 0 to 100) will be considered as
clinically significant.
At an alpha risk of 0.0166, power of 80%, and a per-
centage Φ of 10%, the number of subjects required to
detect a difference of at least 10 points (±11) in quality-
of-life score is at least 70 per group (54 × 1.25), or 140
patients in total.
We thus plan to include 16 patients in each of the 10
participating centers ( eight in each group in each cen-
ter. Participating centres are all specialist cancer insti-
tutes, with a high recruitment potential for this type of
(relatively frequent) patient profile. Indeed, a preliminary
survey performed for the purposes of prior grant appli-
cations suggested that more than 20 such cases per year
are treated in participating centers. Based on these re-
cruitment estimates with an anticipated moderate inclu-
sion rate, the inclusion period is scheduled to last
30 months, and the total duration of the study including
setup, data collection, and analysis will be 42 months.
Statistical analysis
All analyses will be performed on an intention-to-treat
basis. A formal statistical analysis plan will be prepared
before the database lock. Any deviation from the statis-
tical analysis plan will be detailed and discussed in the
study report.
Clinical and sociodemographic variables collected at
baseline will be described as mean ± standard deviation
(SD) for normally distributed continuous variables, the
median (interquartile) range for nonnormally distrib-
uted variables and number (percentage) for qualitative
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questionnaires completed at each measurement point
will be reported.
Primary objective
A treatment group will be considered as superior to the
other if at least one of the three domains of the primary
end point (physical function, overall health status/quality
of life, or fatigue) of the QLQ-C15-PAL questionnaire is
clinically and statistically significantly better, without any
clinically and statistically significant deterioration in at
least one of the other two domains.
Comparison of the three domains of the QLQ-C15-
PAL questionnaire (between the parenteral nutrition and
oral feeding groups) will be performed on an intention-
to-treat basis for all patients randomized and included,
by using ANOVA on scores at 2 months. Analyses will
be adjusted for the presence (or not) of palliative chemo-
therapy. The variation in the score for each domain be-
tween inclusion (day 1) and day 60 will be compared
with ANOVA, taking into account stratification variables
and potential confounding factors, such as center, type
of cancer, and patient characteristics.
Change in quality of life over time
Quality-of-life scores will be generated according to algo-
rithms described in the EORTC scoring manual. The
mechanism of missing scores will be studied and classified
according to the methods of Diggle [26] and Rubin [27]
(that is, MCAR (Missing Completely At Random), MAR
(Missing At Random), and MNAR (Missing Not At Ran-
dom). The mechanism of missing data will be determined
by comparing patients with no missing scores with those
with at least one missing score at baseline, according to
baseline characteristics of patients. If required, more
detailed patterns will be defined. If missing data are
MNAR, multiple imputations may be performed. Other-
wise, simple imputation by the mean will be retained.
The time to quality-of-life score deterioration (TTD)
will be defined as a modality of longitudinal quality-of-life
analysis and will be defined as the time from inclusion in
the study to a first deterioration, with a minimum clinic-
ally significant difference of at least 5 points as compared
with the baseline score, or death of any cause, whichever
occurs first [28,29]. Although three domains of the
EORTC QLQ-C15-PAL are being targeted for the primary
end point, scores from all domains of the questionnaire
will be studied as secondary analyses. The TTD curves will
be calculated by using the Kaplan-Meier method and de-
scribed, by using median and 95% confidence interval
(CI). TTD curves will be compared according to treatment
group by using the log-rank test and univariate Hazard
Ratio with 95% CI. A multivariate Cox regression model
will then be performed to investigate potential prognosticfactors of TTD. All variables collected at baseline
will be tested by univariate analysis. Variables with a
P value ≤0.20 by univariate analysis will be eligible for
inclusion in the multivariate Cox analysis.
Mixed-model analyses of variance for repeated measures
will also be performed to test a time effect, a treatment
effect, and an interaction between time and treatment. If
missing data are not completely at random, a pattern-
mixture model will be used.
Analysis of the secondary end points will focus first on
comparison of overall survival. Overall survival is de-
fined as the time from study registration to death of any
cause. Patients who are lost to follow-up will be counted
at the date of their last follow-up.
For all time-to-event end points, the 95% CI of the
median survival will be calculated with the Brookmeyer
and Crowley method [30]. The two treatment arms will
be compared with the log-rank test.
Hazard ratios with 95% CI will be estimated by using
Cox’s univariate proportional hazards model. Follow-up
will be estimated by using reverse Kaplan estimation.
A multivariate Cox regression model will be performed
to investigate potential prognostic factors. All variables
collected at baseline will be tested in univariate analysis.
Variables with an univariate P value ≤0.20 will be eligible
for multivariate Cox analysis. A bootstrap procedure will
be used to check internal validation of the model. The dis-
criminatory capacity of the model will be assessed with
Harrell C statistic. Reclassification ability will be examined
with Net Reclassification Improvement (NRI) [31] and In-
tegrated Discrimination Improvement (IDI) [32].
Ethics
Research ethics approval
This protocol is governed by French legislation concerning
interventional biomedical research and, as such, was sub-
mitted to the local ethics committee (Comité de Protection
des Personnes Est II) and approved on January 23, 2012,
under the number 11/623. The study was also approved
by the French Health Products Safety Agency (Agence
Nationale de Sécurité du Médicament et des produits de
santé, ANSM) on May 14, 2012. The database was regis-
tered with the French national authority for the protection
of privacy and personal data (Commission Nationale de
l’Informatique et des Libertés, CNIL). Computerised data
are processed anonymously. An anonymous identification
code will be attributed to each participating in the study,
and the list identifying participating patients with their
personal data will be stored by the investigator and kept
strictly confidential and will not be disclosed to the study
sponsor.
To offset any potential remarks on the ethical issues
raised by the use of the Zelen design, we came to an
agreement with the President of the Ethics Committee
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Institutional Review Board of the University Hospital of
Besancon, as well as a local group of patient associations
to obtain their opinion on the choice of randomization
method. The study synopsis, a short note explaining the
specificities of the Zelen design (accompanied by a figure),
and the patient information leaflets from the study were
provided. The study was examined by the Institutional
Review Board who gave their approval, indicating that the
study appeared to protect the patients and was likely the
only means to perform a study of this type.Information and consent
Information will be given to all patients on the day of the
first consultation. Informed-consent forms will be signed
by both the patient and the investigator, with a copy for
each, and the original stored by the investigator. Partici-
pants are informed in the patient-information leaflet that
the data generated by the study will be conserved in elec-
tronic format for 15 years. In particular, it is noted that in-
dividual data relating to them will be accessible only to the
investigator, or to the relevant health authorities for official
inspection or a quality audit by official representatives
appointed by the sponsor.
Contrary to the classic randomization procedure for clin-
ical trials, the Zelen design proposes that randomization be
performed before patients give their consent to participate.
The patient information therefore contains no mention of
the randomization procedure to minimize the difficulty of
obtaining informed consent, thus increasing participation.
Once randomization has been performed, patients assigned
to the intervention group are then approached for consent
(single-consent design). In this design, the patient informa-
tion and informed consent discuss only the modalities re-
lated to the intervention (that is, parenteral nutrition)
inclusion criteria, objectives, composition, expected effects,
foreseeable risks and benefits, contraindications, adminis-
trative issues, follow-up. However, in the ALIM-K study,
the patients in both groups will give consent for completion
of the quality-of-life questionnaire.Discussion
A well-designed, randomized, controlled study compar-
ing parenteral nutrition with oral feeding is needed to
reach a consensus on the best form of nutrition in mal-
nourished patients at the palliative phase of advanced
cancer. Studies of this type have previously been per-
formed in many patient populations, including patients
with cancer [33-37], but with only a very few studies in
patients at the palliative phase [12]. This latter study
highlights the difficulty of performing randomized con-
trolled trials in palliative care, because the inclusion of
the sample size of 309 patients took 6 years.Performing randomized clinical trials on nutrition in pa-
tients at the palliative stage of advanced cancer, a particu-
larly vulnerable population, remains a challenge. It requires
the ultimate respect for the patients, many of whom are to-
tally opposed to the idea of any kind of research at this
stage of their life and illness. Indeed, being too ill was the
most frequently cited motive for refusal to participate in a
randomized study by Rabow et al. [38] comparing the effi-
cacy of palliative care with standard management in out-
patient care for patients with advanced congestive heart
failure, chronic obstructive pulmonary disease, or cancer. It
is often difficult for patients and their families to accept the
idea that research would still be possible at this stage of
their illness, let alone the idea that random allocation might
be the best option, given the medical uncertainty surround-
ing the efficacy of the mode of nutrition to be administered.
Furthermore, randomization for patients in this context
can appear to the patient to “dehumanize” the relation with
caregivers and the healthcare system, which can justifiably
cause considerable worry and anxiety in the face of the
medical community’s uncertainty.
To avoid the possible information bias mentioned and
its associated deleterious effects on participation rates,
we decided to use the Zelen single-consent design for
the ALIM-K study. This choice was approved by the
Ethics Committee, the Institutional Review Board, and a
group representing patient associations. Many experts
initially considered the Zelen method to be a violation of
the ethos, if not the very letter of the law, regarding in-
formed consent [39]. However, the method was found to
be attractive for research in situations of great precar-
iousness and is used in a variety of different contexts
[40]. Patients remain free to express their preference for
another treatment approach at any time.
Nonetheless, recruitment remains challenging for several
reasons. The methodology of the Zelen design used in the
ALIM-K study provides an opportunity to investigate the
factors that influence the decision by patients or physicians
to accept (or not) artificial nutrition in the setting of pallia-
tive care for advanced care. At the palliative stage of cancer,
the main end point is quality of life, even though this term
may appear to be a misnomer to many patients at the end
of life. The QLQ-C15 PAL questionnaire used in our study
presents the advantage of addressing simple issues related
to daily life, and is quick and easy to complete.
Because our randomization procedure takes into con-
sideration the fragility of this patient population, and the
design is close to the reality of routine practice, it will be
interesting to see which factors emerge as predictors of
refusal or acceptance of artificial nutrition.
Trial status
Between May 2012, and April 2013, 13 patients were in-
cluded in two centers to check the feasibility and
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ceptability. Qualitative analyses of these pretest data
confirmed that methods and questionnaires are accept-
able and that the study is feasible. The main adjustment
to result from this test phase was greater precision re-
quired in some of the inclusion criteria.
At the time of submission of the manuscript, the
ALIM-K study is ongoing. All 10 centers were enrolling
progressively, and the last participating center (Lille) was
opened on April 16, 2014. Patient recruitment is not
complete, at the time of submission.
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